drugset / Trial / NCT00601107

A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis

NCT00601107

Phase 2 Completed 111 enrolled Genzyme, a Sanofi Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study was to evaluate the safety and effectiveness of an investigational drug called doxercalciferol in participants with moderate to severe chronic plaque psoriasis, in comparison with a placebo ("sugar pill"). All study related care was provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation was 28 weeks.

Timeline

Start
2008-04
Primary completion
2009-02
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxercalciferol Small molecule 2.5 ug Oral
Subject Doxercalciferol Small molecule 5 ug Oral
Subject Doxercalciferol Small molecule 7.5 ug Oral

Indications